Related Experiment Video
Updated: May 19, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution
Sevcan Atay1, Ibrahim Barista, Fatma Gundogdu
1Hacettepe University, Ankara, Turkey.
Insights
Rapid infusion rituximab (over 90 minutes) is safe and well-tolerated for non-Hodgkin's lymphoma patients receiving second and subsequent cycles. This accelerated infusion method shows no severe infusion-related adverse events.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Rituximab is a chimeric anti-CD20 monoclonal antibody used in cancer therapy.
- Infusion-related reactions are a common concern with monoclonal antibody treatments.
- Optimizing infusion times can improve patient convenience and healthcare efficiency.
Purpose of the Study:
- To evaluate the safety and tolerability of a rapid 90-minute infusion of rituximab.
- To assess infusion-related adverse events in patients with non-Hodgkin's lymphoma receiving accelerated rituximab infusions.
Main Methods:
- Adult patients with non-Hodgkin's lymphoma receiving rituximab were enrolled.
- Cycle 1 rituximab infusion followed standard guidelines; subsequent cycles were infused over 90 minutes.
- Patients were monitored for infusion-related reactions and vital signs throughout the infusion process.
Main Results:
- 75 patients with non-Hodgkin's lymphoma received 372 infusions between July 2006 and December 2008.
- The majority of patients were treated with rituximab combined with chemotherapy (e.g., R-CHOP) or rituximab alone.
- No Grade 3 or 4 infusion-related adverse events were observed during the rapid 90-minute rituximab infusions.
Conclusions:
- A rapid 90-minute rituximab infusion is a safe and well-tolerated option.
- This accelerated infusion schedule is suitable for second and subsequent administrations in non-Hodgkin's lymphoma therapy.
Purpose:
Rituximab is a chimeric anti-CD20 monoclonal antibody. We aimed to explore the safety and tolerability of rapid infusion rituximab, (over 90 minutes) in patients with non-Hodgkin's lymphoma at Hacettepe University Department of Medical Oncology.
Patients And Methods:
Adult patients diagnosed with non-Hodgkin's lymphoma who were to receive rituximab were included in the study. The schedule of administration for cycle 1 was unaltered and delivered according to the product monograph. All subsequent cycles were administered over a total infusion time of 90 minutes (20% of the dose in the first 30 minutes, then the remaining 80% over 60 minutes, total dose delivered in 500 mL). All patients were observed for infusion-related reactions during the rituximab infusion, and vital signs were recorded every 15 minutes.
Results:
From July 2006 to December 2008, 75 patients with non-Hodgkin's lymphoma were treated with rituximab-based chemotherapy. A total of 372 infusions were administered. The majority of patients were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, or rituximab only. The 90-minute rituximab infusion schedule was well tolerated, with no grade 3 or 4 infusion-related adverse events observed.
Conclusion:
A rapid infusion rituximab over 90 minutes is well tolerated and safe when administered as the second and subsequent infusions in the course of therapy.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
